Baricitinib
- Generic Name
- Baricitinib
- Brand Names
- Olumiant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N7O2S
- CAS Number
- 1187594-09-7
- Unique Ingredient Identifier
- ISP4442I3Y
- Background
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
...
- Indication
In the US and Europe, baricitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Baricitinib may be used as monotherapy or in combination with methotrexate or other DMARDs.
...
- Associated Conditions
- Alopecia Areata (AA), Coronavirus Disease 2019 (COVID‑19), Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
COVID-19 VaccinE Response in Rheumatology Patients
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Jeffrey Curtis
- Target Recruit Count
- 1000
- Registration Number
- NCT05080218
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States
🇺🇸University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
A Study of Baricitinib (LY3009104) in Children With COVID-19
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT05074420
- Locations
- 🇺🇸
The University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
🇧🇷Pesquisare Saude, Santo André, São Paulo, Brazil
Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Incepta Pharmaceuticals Ltd
- Target Recruit Count
- 480
- Registration Number
- NCT05056558
- Locations
- 🇧🇩
Dhaka Medical College, Mugda Medical College, Kuwait Bangladesh Friendship Government Hospital, Dhaka, Bangladesh
Efficacy and Safety of Baricitinib in Sjogren's Syndrome
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05016297
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
ConsideRAte Study - Splenic Stimulation for RA
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Galvani Bioelectronics
- Target Recruit Count
- 28
- Registration Number
- NCT05003310
- Locations
- 🇳🇱
Academic Medical Center (AMC) Dept of Rheumatology & Clinical Immunology, Amsterdam, Netherlands
🇳🇱Maxima Medical Center, MMC, Eindhoven, Netherlands
🇺🇸Medvin Research - Whittier, Whittier, California, United States
Baricitinib in Patients With Relapsing or naïve Dermatomyositis
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 62
- Registration Number
- NCT04972760
- Locations
- 🇫🇷
Pitie-Salpêtrière hospital APHP, Paris, France
Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
- Registration Number
- NCT04970719
- Locations
- 🇧🇩
Kurigram Adhunik Sadar Hospital, Kurigram, Bangladesh
🇧🇩Rajshahi Medical College & Hospital, Rajshahi, Bangladesh
🇧🇩Debidwar Upazila Health Complex, Comilla, Bangladesh
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
- Conditions
- Interventions
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 10
- Registration Number
- NCT04901325
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 290
- Registration Number
- NCT04891133
- Locations
- 🇮🇪
Beaumont Hospital, Dublin, Dublin, Ireland
🇧🇪Erasme Hospital, Brussels, Belgium
🇫🇷Hôpital Bichat - Claude Bernard (ICU), Paris, France
Baricitinib in New-onset Type 1 Diabetes
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- St Vincent's Institute of Medical Research
- Target Recruit Count
- 91
- Registration Number
- NCT04774224
- Locations
- 🇦🇺
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
🇦🇺Women's and Children's Hospital Adelaide, North Adelaide, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.